Abstract 124P
Background
BRAF V600E is identified approximately 5-9% of colorectal cancer (CRC) patients. Non-V600E BRAF mutation is characterized a rare molecular subtype. The clinical characteristics and prognostic impact of non-V600 BRAF mutants are not well defined.
Methods
We recruited 829 patients with CRC from our institution. Tissue samples were molecularly tested. Clinical data was retrospectively reviewed and analyzed using Chi-square and t-test. Overall survival (OS) was compared by log-rank test.
Results
All BRAF mutation was detected in 50 (6%) patients including 24 (3%) patients with non-V600 mutations. Patient characteristics and BRAF testing technique were not significantly different based on BRAF status and it was comparable between BRAF V600E and non-V600 groups. There were significantly more ALL RAS and PIK3CA mutations in non-V600 mutant patients. Patients with non-V600 mutation had median OS of 82 months which was longer than BRAF WT, 66 months, and 31 months of BRAF V600E group, respectively (P=0.067). OS according to treatment with anti-EGFR in metastatic CRC patients was not significantly different in both V600E and non-V600 BRAF mutant groups. Table: 124P
BRAF-MT (n=50) | |||||||
BRAF-WT (n=779) | BRAF-MT (n=50) | p-value | V600 (n=26) | non-V600 (n=24) | p-value | ||
Age | 63 (18 - 93) | 65 (19-85) | 66 (19 - 85) | 65 (24 - 83) | |||
Sex | |||||||
Male | 471 (60) | 32 (64) | 0.62 | 15 (58) | 17 (71) | 0.333 | |
Female | 308 (40) | 18 (36) | 11 (42) | 7 (29) | |||
Sidedness | |||||||
Left | 591 (76) | 33 (66) | 0.289 | 12 (70) | 15 (62) | 0.878 | |
Right | 168 (22) | 15 (30) | 7 (27) | 8 (33) | |||
non-specify | 20 (3) | 2 (4) | 1 (4) | 1 (4) | |||
Technique | |||||||
NGS | 547 (70) | 38 (76) | 0.466 | 18 (69) | 20 (83) | 0.26 | |
Pyrosequencing | 84 (11) | 6 (12) | 5 (19) | 1 (4) | |||
PCR | 148 (19) | 6 (12) | 3 (12) | 2 (12) | |||
All RAS mutation | 418 (54) | 8 (16) | <0.001 | 0 | 8 (33) | 0.001 | |
PIK3CA mutation | 94 (12) | 9 (18) | 0.218 | 1 (4) | 8 (33) | 0.009 | |
Recur/Met | (n=575) | (n=35) | (n=19) | (n=16) | |||
Anti-VEGF | 105 (18) | 7 (20) | 0.796 | 2 (11) | 5 (31) | 0.207 | |
Anti-EGFR | 162 (28) | 6 (17) | 0.156 | 3 (16) | 3 (19) | 1 |
Conclusions
Non-V600 BRAF mutation may indicate better prognosis. The difference in treatment effect was not demonstrated in patients with BRAF mutation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Faculty of medicine Ramathibodi Hospital.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
184P - Neutropenia as a predictive and prognostic factor in nanoliposomal-irinotecan/fluorouracil/leucovorin therapy for pancreatic cancer: Findings from the NAPOLEON-2 study (NN-2301)
Presenter: Yuki Sonoda
Session: Poster Display
Resources:
Abstract
185P - Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: A real-world, multicenter study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract
186P - Efficacy and safety of fruquintinib with nab-paclitaxel in advanced G/GEJ cancer after exposure to immune checkpoint inhibitors: A single-center prospective clinical trial
Presenter: Xiaoting Ma
Session: Poster Display
Resources:
Abstract
187P - Neoadjuvant cadonilimab (PD-1/CTLA-4 bispecific antibody) plus transhepatic arterial infusion chemotherapy (HAIC) for resectable multinodular CNLC Ib/IIa hepatocellular carcinoma (Car-Hero)
Presenter: Yongguang Wei
Session: Poster Display
Resources:
Abstract
188P - Impact of metformin, statin, aspirin and insulin on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Presenter: Margherita Rimini
Session: Poster Display
Resources:
Abstract
189P - Safety run-in results from LEAP-014: First-line lenvatinib (len) plus pembrolizumab (pembro) and chemotherapy (chemo) for metastatic esophageal squamous cell carcinoma (ESCC)
Presenter: Shun Yamamoto
Session: Poster Display
Resources:
Abstract
190P - Perioperative camrelizumab combined with chemotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: A single-arm, single-center, phase II clinical trial
Presenter: Jiaxing He
Session: Poster Display
Resources:
Abstract
191P - Predictive value of CXCR6 expression in gastric cancer survival and immune modulation
Presenter: Song-Hee han
Session: Poster Display
Resources:
Abstract
192P - Antiangiogenesis-related adverse events (ARAE) to predict efficacy in patients with advanced gastric cancer (AGC) treated with apatinib + chemotherapy: Results from two prospective studies
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract
193P - Impact of coronavirus disease 2019 on patients with unresectable hepatocellular carcinoma treated with atezolizumab/bevacizumab
Presenter: Hongjae Chon
Session: Poster Display
Resources:
Abstract